Novartis announces pelacarsen Lp(a)HORIZON Phase 3 topline: primary endpoint missed
Novartis announced pelacarsen Phase 3 Lp(a)HORIZON topline results. The study did not meet its primary endpoint to reduce the risk of cardiovascular events, a composite including cardiovascular death and non-fatal myo…
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myo…